Atossa Therapeutics (ATOS) Competitors

Atossa Therapeutics logo
$0.83 +0.02 (+1.87%)
Closing price 02/14/2025 04:00 PM Eastern
Extended Trading
$0.82 -0.01 (-1.23%)
As of 02/14/2025 07:33 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ATOS vs. ZVRA, ATXS, UPB, ANAB, GLUE, RGNX, AURA, TSHA, RVNC, and TERN

Should you be buying Atossa Therapeutics stock or one of its competitors? The main competitors of Atossa Therapeutics include Zevra Therapeutics (ZVRA), Astria Therapeutics (ATXS), Upstream Bio (UPB), AnaptysBio (ANAB), Monte Rosa Therapeutics (GLUE), REGENXBIO (RGNX), Aura Biosciences (AURA), Taysha Gene Therapies (TSHA), Revance Therapeutics (RVNC), and Terns Pharmaceuticals (TERN). These companies are all part of the "pharmaceutical products" industry.

Atossa Therapeutics vs.

Atossa Therapeutics (NASDAQ:ATOS) and Zevra Therapeutics (NASDAQ:ZVRA) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, community ranking, dividends, risk, media sentiment, valuation, earnings, profitability and institutional ownership.

Atossa Therapeutics has a beta of 1.24, indicating that its share price is 24% more volatile than the S&P 500. Comparatively, Zevra Therapeutics has a beta of 2, indicating that its share price is 100% more volatile than the S&P 500.

12.7% of Atossa Therapeutics shares are owned by institutional investors. Comparatively, 35.0% of Zevra Therapeutics shares are owned by institutional investors. 7.6% of Atossa Therapeutics shares are owned by company insiders. Comparatively, 2.4% of Zevra Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Atossa Therapeutics has higher earnings, but lower revenue than Zevra Therapeutics. Zevra Therapeutics is trading at a lower price-to-earnings ratio than Atossa Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Atossa TherapeuticsN/AN/A-$30.09M-$0.22-3.77
Zevra Therapeutics$27.46M15.69-$46.05M-$1.97-4.10

In the previous week, Zevra Therapeutics had 19 more articles in the media than Atossa Therapeutics. MarketBeat recorded 22 mentions for Zevra Therapeutics and 3 mentions for Atossa Therapeutics. Zevra Therapeutics' average media sentiment score of 0.60 beat Atossa Therapeutics' score of 0.51 indicating that Zevra Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Atossa Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Zevra Therapeutics
8 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Atossa Therapeutics currently has a consensus price target of $7.00, suggesting a potential upside of 743.17%. Zevra Therapeutics has a consensus price target of $21.57, suggesting a potential upside of 167.30%. Given Atossa Therapeutics' higher probable upside, equities analysts clearly believe Atossa Therapeutics is more favorable than Zevra Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Atossa Therapeutics
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00
Zevra Therapeutics
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
2 Strong Buy rating(s)
3.25

Atossa Therapeutics has a net margin of 0.00% compared to Zevra Therapeutics' net margin of -342.63%. Atossa Therapeutics' return on equity of -35.74% beat Zevra Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Atossa TherapeuticsN/A -35.74% -33.51%
Zevra Therapeutics -342.63%-159.54%-51.50%

Atossa Therapeutics received 209 more outperform votes than Zevra Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Zevra Therapeutics an outperform vote while only 65.22% of users gave Atossa Therapeutics an outperform vote.

CompanyUnderperformOutperform
Atossa TherapeuticsOutperform Votes
240
65.22%
Underperform Votes
128
34.78%
Zevra TherapeuticsOutperform Votes
31
100.00%
Underperform Votes
No Votes

Summary

Atossa Therapeutics and Zevra Therapeutics tied by winning 9 of the 18 factors compared between the two stocks.

Get Atossa Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ATOS and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ATOS vs. The Competition

MetricAtossa TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$104.44M$6.84B$5.76B$9.22B
Dividend YieldN/A2.90%5.27%4.00%
P/E Ratio-3.779.7126.2219.44
Price / SalesN/A290.45456.5777.34
Price / CashN/A75.4646.0638.90
Price / Book1.145.537.355.05
Net Income-$30.09M$123.46M$3.19B$222.81M
7 Day Performance1.23%1.37%1.69%1.29%
1 Month Performance0.54%2.09%4.13%1.52%
1 Year Performance-17.80%1.28%22.24%16.53%

Atossa Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ATOS
Atossa Therapeutics
1.2181 of 5 stars
$0.83
+1.9%
$7.00
+743.2%
-17.8%$104.44MN/A-3.778Short Interest ↑
ZVRA
Zevra Therapeutics
2.1865 of 5 stars
$7.57
-2.6%
$21.57
+185.1%
+17.6%$403.82M$27.46M-3.8420Insider Trade
ATXS
Astria Therapeutics
1.7553 of 5 stars
$7.10
-0.1%
$25.67
+261.5%
-49.5%$402.66MN/A-3.4130
UPB
Upstream Bio
N/A$7.49
-5.5%
$56.50
+654.8%
N/A$401.25MN/A0.0038
ANAB
AnaptysBio
3.9018 of 5 stars
$12.95
-11.2%
$40.08
+209.5%
-12.0%$396.28M$57.17M-2.14100Short Interest ↓
Analyst Revision
GLUE
Monte Rosa Therapeutics
2.6489 of 5 stars
$6.44
-4.4%
$14.00
+117.3%
+13.8%$395.49MN/A-3.5290Short Interest ↓
Positive News
RGNX
REGENXBIO
4.4196 of 5 stars
$7.84
-4.6%
$35.64
+354.8%
-61.2%$388.73M$84.33M-1.56370Analyst Downgrade
AURA
Aura Biosciences
3.108 of 5 stars
$7.77
-0.4%
$23.00
+196.2%
-10.1%$387.61MN/A-4.4950Short Interest ↓
TSHA
Taysha Gene Therapies
2.7131 of 5 stars
$1.86
+6.0%
$6.63
+257.1%
-14.7%$382.21M$15.45M2.96180
RVNC
Revance Therapeutics
4.2725 of 5 stars
$3.65
flat
$8.39
+129.7%
N/A$381.02M$234.04M-1.89500Analyst Forecast
TERN
Terns Pharmaceuticals
4.5472 of 5 stars
$4.46
-0.6%
$18.30
+310.8%
-48.3%$378.41MN/A-3.7840

Related Companies and Tools


This page (NASDAQ:ATOS) was last updated on 2/17/2025 by MarketBeat.com Staff
From Our Partners